前列腺疾病患者血清TPSA、FPSA和PAP的检测及其意义  

Determination and Significance of Serum TPSA 、PSA and PAP in Patients with Prostate Diseases

作　　者：钟琼[1] 袁汉尧[1] 李少华[1] 

机构地区：[1]广东医学院附属医院检验科,湛江524001

出　　处：《数理医药学杂志》2004年第2期122-123,共2页Journal of Mathematical Medicine

摘　　要：为探讨总前列腺特异性抗原 (TPSA)、游离前列腺特异性抗原 (FPSA)、前列腺酸性磷酸酶 (PAP)的检测对前列腺疾病的诊断价值 ,采用双抗体夹心酶联免疫 (ELISA)法对 3 8例前列腺癌、85例前列腺良性疾病和 40例正常人血清中 TPSA、FPSA和PAP水平进行了检测。结果显示 ,前列腺癌患者血清中 TPSA、 FPSA和 PAP水平均显著高于前列腺良性疾病组和正常对照组 (P<0 .0 1) ,F/ T比值前列腺癌组明显低于前列腺良性疾病组和正常组 (P<0 .0 1) ,前列腺良性疾病组与正常组无明显差别。To investigate the clinical value of serum total prostatic-specific antigen(TPSA)、free prostatic-specific antigen(FPSA) and prostatic acid phosphatase(PAP); determination in diagnosis of prostate diseases. The levels of serum TPSA、FPSA and PAP in 38 prostate cancer patients, 85 prostate benign disease patients and 40 normal volunteers were detected by ELISA. The levels of serum TPSA、FPSA and PAP in prostate cancer group were significantly higher than those in prostate benign disease and normal controls groups (P<0.01). F/T was lower in prostate cancer group than that in prostate benign disease and normal controls groups(P<0.01).

关 键 词：前列腺疾病 血清 TPSA FPSA PAP 检测 游离前列腺特异性抗原 前列腺酸性磷酸酶 总前列腺特异性抗原 

分 类 号：R697.3[医药卫生—泌尿科学] R446.112[医药卫生—外科学]